Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Global Hemophilia B Market 2015-2019 - Industry Analysis

Published: Sep-2015 | Format: PDF | Technavio | Number of pages: 60 | Code: MRS - 35080


Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.

The analysts forecast global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.

The report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Baxter
  • Grifols
  • Novo Nordisk
  • Pfizer

Other prominent vendors

  • Alnylam
  • Amarna
  • Asklepios
  • Biogen
  • Catalyst Biosciences
  • CSL Behring
  • Dimension Therapeutics
  • Dong-A Scio
  • Emergent BioSolutions

Key market driver

  • Prophylactic treatment
  • For a full, detailed list, view our report

Key market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Key market trend

  • New technological advancements
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors


Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Disease overview
Understanding the disease
Epidemiology

PART 07: Pipeline portfolio
Key information of few pipeline candidates

PART 08: Market segmentation by disease severity
Mild hemophilia B
Moderate hemophilia B
Severe hemophilia B

PART 09: Market segmentation by disease management
On-demand therapy
Prophylactic therapy
Inhibitor therapy

PART 10: Geographical segmentation

PART 11: Market drivers
Focus on prophylactic treatment
Drugs with prolonged action
Patient assistance programs

PART 12: Impact of drivers

PART 13: Market challenges
High cost of therapy
Low diagnosis rate in developing countries
Complications of available therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends
Advances in technology
Strategic alliances
Development of gene therapy products

PART 16: Vendor landscape
Competitive scenario
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors

PART 17: Key vendor analysis
Baxter
Grifols
Novo Nordisk
Pfizer

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global hemophilia B market 2014-2019 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Global cases of hemophilia B 2010-2013
Exhibit 05: Cases of Hemophilia B by region 2012
Exhibit 06: Cases of hemophilia B by region 2013
Exhibit 07: Global hemophilia B market segmentation by disease severity
Exhibit 08: Global hemophilia B market segmentation by disease severity 2014
Exhibit 09: Treatment of severe hemophilia B 2014
Exhibit 10: Global hemophilia B market segmentation by disease management
Exhibit 11: Share of prophylactic therapy by region 2014
Exhibit 12: Types of prophylaxis
Exhibit 13: Global hemophilia B market segmentation by disease management 2014
Exhibit 14: Global hemophilia B market segmentation 2014
Exhibit 15: Global hemophilia B market segmentation by revenue 2014 ($ billions)
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Baxter: Global sales of hemophilia B drugs 2014-2017 ($ millions)
Exhibit 19: Baxter: Key takeaways
Exhibit 20: Grifols: Key takeaways
Exhibit 21: Novo Nordisk: Global sales of NovoSeven 2011-2014 ($ millions)
Exhibit 22: Novo Nordisk: Key takeaways
Exhibit 23: Pfizer: Global sales of BeneFIX 2011-2014 ($ millions)
Exhibit 24: Pfizer: Key takeaways
Exhibit 25: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 26: Novo Nordisk: Business segmentation by revenue 2013 and 2014
Exhibit 27: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 28: Novo Nordisk: R&D expenditure 2014

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2500 View Pricing